Shanghai Laisi (002252.SZ): SR604 injection enters Phase IIb clinical trial research.

date
08/07/2025
Zhtng Cijng APP news, Shanghai Raas (002252.SZ) announced that the company recently publicized the registration information of Phase IIb clinical trials on the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform. The trial is titled: Evaluation of the safety, tolerance, efficacy, PK/PD characteristics of SR604 injection in patients with hemophilia A/B and congenital factor VII deficiency: an open, multicenter Phase I/II clinical trial.